BioSpace News Archive

A roundup of life sciences companies raking in the cash.

Detecting the presence of SARS-CoV-2 in asymptomatic individuals has been a challenge not even PCR – the gold standard of testing – can adequately address. Now two companies have developed novel solutions with the sensitivity and specificity needed to provide ample warning.

A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.

Novartis’ Entresto is well on its way to receiving approval as a treatment for heart failure patients following overwhelming support from a U.S. Food and Drug Administration (FDA) advisory committee.

After four people in the Pfizer-BioNTech’s and three people in Moderna’s COVID-19 vaccine trials developed temporary facial weakness or paralysis, some people became concerned that it could happen to them. But experts suggest that the condition, known as Bell’s palsy, is fairly prevalent in the population and generally transient.

vTv Therapeutics, based in High Point, North Carolina, announced that its Phase II Elevage study of azeliragon in mild Alzheimer’s disease and type 2 diabetes failed to hit its primary objective.

It’s been a busy day so far for biopharma news and updates. Read on for more.

Novartis’ Iptacopan isn’t the only drug to receive Breakthrough Therapy designation this week. Several other experimental treatments were also awarded the designation.

Launching with hearty Series A rounds, these new companies are ready to run.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.